GILEAD SCIENCES $56.30

up +1.34


17/5/2013 07:17 PM  |  NASDAQ : GILD  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 117% - GILD has outperformed the S&P 500 by 92%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga

  2. Gilead Sciences Inc (GILD) Chairman and CEO John C Martin sells ...

    GuruFocus

  3. YM Biosciences Wins Final Court Order Approving Plan of ...

    Benzinga

  4. UPDATE: Gilead Posts Upbeat Q4 Results

    Benzinga

  5. Gilead ekes out higher profit

    Investors Business Daily

  6. Morgan Stanley Reiterates Overweight Rating on Gilead Sciences on ...

    Benzinga

  7. Piper Jaffray Reiterates Overweight Rating, $44 PT on Gilead Sciences

    Benzinga

  8. US Stock Futures Flat Ahead Of Factory-Orders Data

    Benzinga

  9. Earnings Scheduled For February 4, 2013

    Benzinga

  10. Gilead Stock Hits High Ahead Of Q4 Earnings Report

    Investors Business Daily

  11. UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead ...

    Benzinga

  12. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga

  13. Morgan Stanley Sees Possible Near-Term Increase in M&A, Unveils ...

    Benzinga

  14. Stevie Cohen On Board with Real Estate Betting, Despite SEC Probe

    GuruFocus

  15. Bristol-Myers' $1 Billion Drug at Center of Debate Over HIV ...

    YCharts

  16. 4 Health Care ETFs Your Broker Forgot to Mention

    Benzinga

  17. Gilead Sciences Inc (GILD) Chairman and CEO John C Martin sells ...

    GuruFocus

  18. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga

  19. Visa, SolarWinds Lead Healthy Profit Margins Screen

    Investors Business Daily

  20. UPDATE: Bloom Burton Downgrades YM BioSciences to Hold Post Gilead ...

    Benzinga

  21. Lilly Sends Drug Back To Lab

    Investors Business Daily

  22. Benzinga's M&A Chatter for Wednesday December 12, 2012

    Benzinga

  23. J.P. Morgan Reiterates Overweight Rating on Gilead Sciences

    Benzinga

  24. These ETFs Are Awash in 2013 Takeover Targets

    Benzinga

  25. Gilead Acquiring YM Biosciences For Cancer Drug

    Investors Business Daily

  26. UPDATE: Gilead to Buy YM BioSciences for $2.95/Share in Cash

    Benzinga

  27. A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)

    Benzinga

  28. Amgen, Gilead, Regeneron Among 7 Best Biotech Stocks

    Investors Business Daily

  29. Gilead Sciences Inc (GILD) Chairman and CEO John C Martin sells ...

    GuruFocus

  30. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga

  31. RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November

    Benzinga

  32. Starbucks, Gilead Stocks Led S&P 100 November Winners

    Investors Business Daily

  33. Starbucks, Gilead Stocks Led S&P 100 November Winners

    Investors Business Daily

  34. Starbucks, Gilead Stocks Led S&P 100 November Winners

    Investors Business Daily

  35. Gilead hep-C drug passes test

    Investors Business Daily

  36. EC Approves Gilead's Viread for HIV-1 Infection in Children, ...

    Benzinga

  37. Gilead Hep C Drug Meets Expectations In Phase 3 Trial

    Investors Business Daily

  38. Gilead Announces Sustained Virologic Response Rate of 78% from ...

    Benzinga

  39. Weekly Top Insider Sells: NOW, FB, GILD, and ISRG

    GuruFocus

  40. Deere, Sherwin-Williams Lead Big-Cap Growth Stocks

    Investors Business Daily

  41. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus

  42. Gilead Announces Results from Two Phase 3 Stribild HIV Studies

    Benzinga

  43. Gilead Sciences Inc (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  44. Gilead Sciences Inc (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  45. Gilead Sciences Inc (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  46. Gilead Sciences Inc (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  47. UPDATE: BMO Capital Markets Reiterates Gilead Sciences at ...

    Benzinga

  48. UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on ...

    Benzinga

  49. UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV ...

    Benzinga

  50. Stocks Hitting 52-Week Highs

    Benzinga

  51. Gilead Hits High On Drug Data

    Investors Business Daily

  52. Goldcorp, Host Of Financials Lead Big-Cap Stocks

    Investors Business Daily

  53. Gilead Stock Pops On Hepatitis C Drug Results

    Investors Business Daily

  54. Stocks End Mixed As Volume Dries Up

    Investors Business Daily

  55. Wedgewood Partners' David Rolfe Comments on Gilead Sciences

    GuruFocus

  56. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga

  57. Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes ...

    Benzinga

  58. Stocks Hitting 52-Week Highs

    Benzinga

  59. Stocks Climb In Quiet Trade; Gilead Sciences Hits New High

    Investors Business Daily

  60. Mid-Morning Market Update: Markets Continue Cautious Rally; ...

    Benzinga

  61. Gilead Stock Pops On Hepatitis C Drug Results

    Investors Business Daily

  62. Gilead Announces Positive Hepatitis C Data

    Benzinga

  63. Gilead Sciences Inc. Reports Operating Results (10-Q)

    GuruFocus

  64. Gilead Sciences Inc (GILD) President and COO John F Milligan sells ...

    GuruFocus

  65. Gilead Sciences Inc (GILD) Chairman and CEO John C Martin sells ...

    GuruFocus

  66. Gilead Sciences Inc (GILD) SVP, CFO Robin L Washington sells 2,925 ...

    GuruFocus

  67. Edward Owens' Vanguard Health Care Fund Does More Shedding Than ...

    GuruFocus

  68. Gilead's Once-Daily Novel Prodrug for the Treatment of HIV Meets ...

    Benzinga

  69. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga

  70. Gilead Sciences, Inc. (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  71. S&P Likes a Trio of Biotech ETFs

    Benzinga

  72. UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on ...

    Benzinga

  73. UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on ...

    Benzinga

  74. IBD 50: Alexion Earnings Beat Estimates; Stock Up

    Investors Business Daily

  75. Boeing, Panera Bread Jump As Stock Futures Strengthen

    Investors Business Daily

  76. Gilead Profit, Sales Beat Estimates As HIV Drugs Boom

    Investors Business Daily

  77. Amgen, Gilead Q3 Profits Top

    Investors Business Daily

  78. Alexion Earnings Expected To Grow, But Stock Slides

    Investors Business Daily

  79. Big Caps Taking Heat; Alexion Breakout Crumbling

    Investors Business Daily

  80. Apple Earnings Lead 5 IBD 50 Tech Reports This Week

    Investors Business Daily

  81. Gilead, Amgen Earnings To Launch Busy Biotech Week

    Investors Business Daily

  82. Apple Earnings Lead 5 IBD 50 Tech Reports This Week

    Investors Business Daily

  83. Medical, Cable, Credit Card Stocks Top IBD Big Cap 20

    Investors Business Daily

  84. Abbott, Bristol-Myers Pop On Hepatitis C Drug News

    Investors Business Daily

  85. Pharma's March Into Emerging Markets Hits Yet Another Rough Spot

    YCharts

  86. Gilead Sciences Inc. (GILD) President and COO John F Milligan ...

    GuruFocus

  87. Gilead Sciences Inc. (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  88. Gilead Sciences

    Investors Business Daily

  89. Gilead Sciences Inc. (GILD) Chairman and CEO John C Martin sells ...

    GuruFocus

  90. Gilead Sciences Inc. (GILD) Chairman and CEO John C Martin sells ...

    GuruFocus

  91. Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

    Benzinga

  92. Stocks Give Back Some of Early Gains After Auto-Sales Data

    At Market Intelligence Center

  93. Several Big Cap 20 Stocks Hit New Highs, In Buy Area

    Investors Business Daily

  94. Stocks Start Fourth Quarter Higher

    At Market Intelligence Center

  95. Analyst Upgrades: Gilead Sciences, Aruba Networks, and Allscripts ...

    By SchaeffersResearch

  96. Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)

    Benzinga

  97. Vertex Kills One HCV Drug, But Another Shows Promise

    Investors Business Daily

  98. Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL

    GuruFocus

  99. Gilead Sciences Inc. (GILD) SVP, CFO Robin L Washington sells ...

    GuruFocus

  100. Race For Next Hepatitis C Drug Gets Tighter

    Investors Business Daily
People viewing GILD also viewed: , , , , , ,
Marketplace
Trading Center